This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Oral Apremilast Demonstrated Rapid, Clinically Significant Improvements In Oral Ulcers In Patients With Behçet’s Disease In A Phase II Trial

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today presented phase II trial (BCT-001) results of apremilast, the Company’s first-in-class, oral, targeted inhibitor of phosphodiesterase 4 (PDE4), in patients with Behçet’s disease. The findings were presented at the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting in San Diego. These results have been featured as part of the official ACR press program, which highlights data considered representative of the highest quality and most meaningful research presented at the ACR annual meeting.

Behçet’s disease is a rare and chronic inflammatory disorder characterized by recurrent oral and genital ulcers, skin and eye lesions (which may cause blindness) and joint inflammation. Inflammation may also affect the brain and gastrointestinal tract.

These data, which were also presented at the European League Against Rheumatism (EULAR) annual meeting this year in June, showed that significantly more patients on apremilast achieved a complete response (were free from active oral ulcers) at week 12 compared with those on placebo (apremilast, 71%; placebo, 29%; p<0.0001). Among patients with genital ulcers at baseline (n=16), 100% of those receiving apremilast had a complete response at week 12 compared with 50% of those receiving placebo ( p=0.036).

“Behçet’s disease can have a severe negative impact on patients’ quality of life, and there are limited therapies available, so there is a clear need for a new therapy to help this patient population,” said Gulen Hatemi, M.D., Associate Professor, Cerrahpasa Medical School, Istanbul, Turkey. “We are encouraged by the rapid response seen in this important phase II study and by apremilast’s potential to treat oral ulcers in this orphan disease.”

The beneficial effect of apremilast on oral ulcers reached a stable effect within two weeks and was sustained while patients remained on treatment.

At week 12, apremilast also improved several patient-reported outcome scores, including the Behçet’s disease current activity form (BDCAF), Behçet’s syndrome activity score (BSAS) and Behçet’s disease quality of life (QoL) instrument. Improvement in oral ulcer pain was also significantly higher with apremilast than with placebo (apremilast, -44.7 ± 24.30; placebo, -16.0 ± 32.54; p<0.0001).

The type and severity of adverse events (AEs) were comparable to the known apremilast safety profile. In BCT-001, treatment-emergent adverse events (TEAE), including severe and serious adverse events (SAEs) and withdrawal due to adverse events, were comparable between 30 mg twice daily (BID) and placebo. None of the SAEs in the apremilast group were reported more than once. Out of the five most common TEAEs in the 30 mg BID group, two (headache and Behçet’s syndrome/flare) were comparable to placebo, while nausea, diarrhea and vomiting were reported more frequently with APR 30 mg BID.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs